Zatolmilast not checked
Tetra Discovery Partners · BPN14770
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “25mg zatolmilast/BPN14770 (Adults) or 15 mg zatolmilast/BPN14770 (Adolescents \<43 kg)”In the company’s words, NCT05367960 on ClinicalTrials.gov
- Tested for
- Fragile X Syndrome, Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder
- Main trialPhase 3
- “This is a 4-year, open-label extension (OLE) study for subjects completing one of two double-blind clinical trials with BPN14770, Study BPN14770-CNS-301 (in adult males) and Study BPN14770-CNS-204 (in adolescent males).”In the company’s words, NCT05367960 on ClinicalTrials.gov
- Other names
- BPN14770
Other drugs for Fragile X Syndrome
Coming up2
- 30 Sep 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Sep 2027 | An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome | |
| Phase 2Active, not recruiting | 31 Dec 2027 | Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS]) | |
| Phase 3Completed | 18 Jul 2025 | A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome | |
| Phase 2/3Completed | 2 Sep 2025 | A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome | |
| Phase 2Completed | 4 Feb 2020 | Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's Subjects | |
| Phase 2Completed | 31 Jul 2020 | A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome | |
| Phase 1Withdrawn | 30 Apr 2020 | A Phase 1, Open-Label, PET Study of T2310 & BPN14770 | |
| Phase 1Completed | 31 Jul 2025 | A Study to Assess the Effects of BPN14770 on Rosuvastatin | |
| Phase 1Completed | 26 Nov 2025 | Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy Controls | |
| Phase 1Completed | 15 Dec 2025 | Study of BPN14770 in Participants With Severe Renal Impairment and Healthy Controls |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026